Such an investigation would provide interesting ideas for the relief of MVK inhibition in patients with autoinflammatory disorders caused by a mevalonate kinase (MK) deficiency [48] and for the design of new MVK inhibitors, which are being considered as potential drugs for the treatment of cardiovascular diseases and cancer [49] and as antibacterial agents [50]. This evidence concerns the gene MVK and cancer.